This article is more than 5 years old. Information may no longer be current.
VIDEO: Expert highlights top takeaways from long-term follow-up of STICH trial
Click Here to Manage Email Alerts
CHICAGO — In this video exclusive, Gregg W. Stone, MD, discusses new 10-year data from the STICH trial and future directions for CABG compared with medical therapy alone in patients with ischemic cardiomyopathy.
The STICH trial included 1,212 patients with left ventricular ejection fraction 35% and CAD suitable for CABG who were randomly assigned to receive guideline-directed medical therapy alone or undergo CABG along with guideline-directed medical therapy. Dubbed the STICHES trial, long-term data were presented at the American College of Cardiology Scientific Session.
The results showed that at 10 years there was a survival advantage with CABG plus medical therapy compared with medical therapy alone.
These data established “an important role for coronary revascularization, particularly with surgery, in these very adverse-event-rich patients,” said Stone, professor of medicine at Columbia University; director of cardiovascular research and education at Columbia University Medical Center/NewYork-Presbyterian Hospital; co-director of medical research and education at the Cardiovascular Research Foundation; and Cardiology Today’s Intervention Editorial Board member. “Further studies are required to determine whether assessing the amount of myocardial variability or ischemia at baseline will help differentiate which patients will benefit, but for now it also shows the importance of long-term follow-up after studies, especially when there are trends toward evidence of possible benefit present from shorter-term follow-up.”